Mumbai-based D2C health and nutrition startup TruNativ has raised $30M (₹290 Cr) in a Series B funding round led by global healthcare investor OrbiMed Advisors LLC, as publicly reported on 16 June 2026. The round includes both primary investment and secondary exits by early backers, marking a significant liquidity event alongside fresh capital for the company.
Quick Highlights
- Founders: Pranav Malhotra, Mamta Malhotra, Eeshaan Merchant
- Lead Investor: OrbiMed Advisors LLC
- Participating Investors: Secondary exits by 100Unicorns, Rainmatter, and Venture Catalysts; Emami diluted its stake from 19% to 10%
- Investor Background: OrbiMed is a globally focused healthcare investment firm making its first consumer nutrition bet in India
- Headquarters: Mumbai, India
- Announcement Date: 16 June 2026
Funding Breakdown
Use of Funds
TruNativ intends to deploy the proceeds across several growth priorities: broadening its offline distribution footprint across D2C, quick commerce, modern trade, and pharmacy channels; scaling its B2B2C ingredient business; establishing a new R&D centre; and funding international market entries in the UAE and Singapore.
Funding Timeline
This Series B round of $30M (₹290 Cr) is the latest disclosed funding milestone for TruNativ. Earlier backers including 100Unicorns, Rainmatter, Venture Catalysts, and Emami had participated in prior rounds, with several now partially exiting via the secondary component of this transaction.
Expansion Plans
On the international front, TruNativ is targeting launches in the UAE and Singapore as its first overseas markets. Domestically, the company plans to deepen its retail presence across offline channels, complementing its existing digital footprint with broader in-store availability through pharmacies, modern trade outlets, and quick commerce platforms.
Significance
TruNativ’s Series B arrives on the back of strong financial momentum — the company reported revenue of ₹130 Cr in FY26, representing 350% year-on-year growth, according to public filings. The round’s structure, combining primary capital with early-backer secondaries and partial dilution by Emami, reflects the maturing of the cap table and validates the brand’s commercial traction. OrbiMed Advisors’ participation is particularly notable: the global healthcare fund has not previously backed a consumer nutrition brand in India, signalling growing institutional conviction that science-led nutrition can scale into a meaningful healthcare adjacency. For the broader D2C health and nutrition segment, this deal underscores rising investor appetite for brands that combine consumer reach with defensible ingredient and R&D capabilities.
These details have been verified against multiple publicly available reports as of 16 June 2026.
For more coverage of deals like this, follow startup funding news on The Courtroom.
Disclaimer: This report is compiled from publicly available sources and is for informational purposes only; funding figures are as publicly reported and may be subject to change.
